Preclinical testing has suggested that AIR-001 increases functional AAT protein levels and could address the lung and liver manifestations of the disease.

In its third major acquisition in the past six weeks, Gilead is buying a company that will add NaPi2b- and 5T4-targeting agents to its portfolio.

The trial is evaluating how the disclosure of polygenic risk scores for cardiovascular disease affects patients' outcomes.